MaxCyte (MXCT) has released an update.
MaxCyte, Inc. has streamlined operations, resulting in a 15% reduction in its workforce, to enhance efficiency and drive long-term growth. This restructuring, combined with strategic initiatives, is expected to save the company $5.8 million in 2025 and boost its 2024 core revenue growth by 6% to 8%. The company remains optimistic about its future in the cell therapy market, projecting a strong finish to the year.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.